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Yellow fever (YF) is a mosquito-transmitted viral disease that
causes tens of thousands of deaths each year despite the long-
standing deployment of an effective vaccine. In its most severe
form, YF manifests as a hemorrhagic fever that causes severe dam-
age to visceral organs. Although coagulopathy is a defining fea-
ture of severe YF in humans, the mechanism by which it develops
remains uncertain. Hepatocytes are a major target of yellow fever
virus (YFV) infection, and the coagulopathy in severe YF has long
been attributed to massive hepatocyte infection and destruction
that results in a defect in clotting factor synthesis. However, when
we analyzed blood from Brazilian patients with severe YF, we
found high concentrations of plasma D-dimer, a fibrin split prod-
uct, suggestive of a concurrent consumptive process. To define the
relationship between coagulopathy and hepatocellular tropism, we
compared infection and disease in Fah−/−, Rag2−/−, and Il2rɣ−/− mice
engrafted with human hepatocytes (hFRG mice) and rhesus ma-
caques using a highly pathogenic African YFV strain. YFV infection
of macaques and hFRG mice caused substantial hepatocyte infec-
tion, liver damage, and coagulopathy as defined by virological,
clinical, and pathological criteria. However, only macaques devel-
oped a consumptive coagulopathy whereas YFV-infected hFRG
mice did not. Thus, infection of cell types other than hepatocytes
likely contributes to the consumptive coagulopathy associated
with severe YF in primates and humans. These findings expand
our understanding of viral hemorrhagic disease and associated
coagulopathy and suggest directions for clinical management of
severe YF cases.
yellow fever virus | coagulopathy | pathogenesis | D-dimer | hepatitis
Yellow fever (YF) is caused by the yellow fever virus (YFV),an enveloped positive-sense RNA virus (family: Flaviviridae;
genus: Flavivirus) that is transmitted by mosquitoes (1). Prior to
the 20th century, YF was an epidemic disease that caused sub-
stantial morbidity and mortality throughout Africa and the
Americas. While mosquito control measures and vaccination
campaigns have curbed the spread of YFV in urban centers, a
sylvatic reservoir is maintained in mosquitoes and nonhuman
primates (NHP) in the tropical rainforests of Africa and South
America (2–4). Activities that bring humans into contact with
infected mosquitoes can result in zoonotic transmission of YFV,
initiating outbreaks that are sustained in more densely populated
areas by the anthropophilic Aedes aegypti mosquito. Recently,
outbreaks of YF have occurred in Angola (2016) (5), the
Democratic Republic of Congo (2016), Brazil (2016 to 2019) (6,
7), and Nigeria (2018 to 2019) (8). The World Health Organi-
zation (WHO) estimates an incidence of 200,000 YF cases per
year, leading to ∼30,000 to 60,000 deaths with the majority oc-
curring in sub-Saharan Africa (9). Overall, 47 countries in Africa
and the Americas are within the modern YFV-endemic zone,
with 600 to 700 million people at risk for infection and an ad-
ditional 400 million requiring vaccination to achieve the 80%
herd immunity threshold that prevents urban YFV transmission
(9–11). Although the YFV-17D live-attenuated vaccine is highly
effective, production issues have resulted in global shortages
(11–13). The expansion of Aedes mosquitos into Asia, Oceania,
Central America, and North America has also raised concerns
that YFV could spread into regions with large numbers of un-
vaccinated individuals and ecosystems that could support new
sylvatic reservoirs (3, 14).
YF begins as a nonspecific febrile illness, from which the
majority of infected individuals recover. However, ∼30% of cases
progress to a more severe form of the disease characterized by
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multiorgan failure, coagulopathy, hemorrhage, and shock. Ap-
proximately 50% of these severe cases are fatal (15, 16). Based
on pathological studies, it has been presumed that the infection
and injury of hepatocytes is central to the development of co-
agulation abnormalities and the resulting hemorrhage in YF.
Hepatocytes are the principal producer of most circulating co-
agulation factors, and a decrease in factor production occurs
after massive hepatocyte injury (2, 15, 16). However, YFV has a
broad cellular tropism, and recent evidence suggests that extra-
hepatic targets of infection may contribute to the pathogenesis of
severe YF (17–21). Indeed, it has been speculated that decreased
clotting factor production alone cannot explain the extent of
coagulopathy observed in severe YF and that a consumptive
coagulopathy (which is a major component of the clinical disease
process known as disseminated intravascular coagulopathy
[DIC]) occurs as part of YF pathogenesis (15, 22). Consumptive
coagulopathy contributes to the pathogenesis of other viral
hemorrhagic fevers including Ebola virus (EBOV), as evidenced
by a direct correlation between EBOV mortality and the primary
laboratory measure of clotting factor consumption, plasma
D-dimer concentration (23). Although treatment of YF patients
with plasma exchange, which restores coagulation system func-
tion, has been used as an intervention to reduce the case fatality
rate of YF (24), our understanding of how coagulopathy de-
velops in severe YF remains limited (15, 17, 18, 22).
Given that various hepatic disease processes can tip the bal-
ance of the coagulation system into hypo- or hyper-coagulable
states (both of which can manifest as hemorrhage) (25), we first
set out to identify the type of coagulopathy that predominates in
severe YF. To do this, we quantified plasma concentrations of
D-dimer—a fibrin split product generated only in hyper-
coagulable (i.e., consumptive) states—in hospitalized patients
with laboratory-confirmed YFV infection and in experimentally
infected rhesus macaques. In these hosts, we found high con-
centrations of D-dimer, indicative of a consumptive coagulop-
athy. Next, we investigated the relationship between hepatocyte
infection and coagulopathy in YF. For this, we developed a
unique YFV infection model in fumarylacetoacetate hydrolase
[Fah]−/−, Rag2−/−, and Il2rɣ−/− (FRG) chimeric mice. Wild-type
(WT) mice are naturally resistant to hepatic YFV infection via
peripheral routes of inoculation and do not develop YF-induced
hepatic disease or coagulopathy (26–30). However, FRG mice
have three genetic lesions (Fah−/−, Rag2−/−, and Il2rɣ−/− on a
C57BL/6J background), which, together with specifically timed
dietary modifications, facilitate the durable replacement of mu-
rine hepatocytes with transplanted human hepatocytes (31).
FRG mice engrafted with human hepatocytes (hFRG) have two
theoretical advantages for study of YFV pathogenesis and coa-
gulopathy: human-origin hepatocytes that are susceptible to
YFV infection and a humanized clotting cascade that can de-
velop consumptive coagulopathy. Infected mice with human
hepatocytes (hFRG) developed disease that recapitulated many
features of YF in humans including massive hepatic infection
and injury. However, YFV-infected hFRG mice did not develop
a consumptive coagulopathy, suggesting that infection of hepa-
tocytes is not the sole determinant of coagulopathy and hemor-
rhage in severe YF in humans.
Results
Coagulopathy in Human YF Is Consumptive. We quantified plasma
D-dimer concentrations in patients with laboratory-confirmed
YFV infection who were hospitalized in São Paulo, Brazil, dur-
ing the 2018 to 2019 epidemic. Although previous analysis of this
cohort (32) had demonstrated coagulopathy using a prothrombin
time (PT) assay, the blood concentration of D-dimers, and thus
the mechanism of coagulopathy, were not evaluated. We found
that 29 of 33 (88%) patients had markedly elevated D-dimer
concentrations during their hospitalization, with 13 of 33 (39%)
having levels above the upper limit of assay quantification (10,000
ng/mL, or 200-fold greater than the upper limit of the reference
range).
YFV Infects Human Hepatocytes in hFRG Mice. To define the rela-
tionship between coagulopathy and YFV hepatocellular tropism,
we compared infection of hFRG mice to age- and diet-matched
WT C57BL/6J mice, FRG mice engrafted with syngeneic mouse
hepatocytes (muFRG), and rhesus macaques (Macacca mulatta),
the gold-standard animal model of viscerotropic/hemorrhagic
YF disease (15, 20, 22, 33, 34). Mice were inoculated intrave-
nously (i.v.) with 2 × 105 focus-forming units (FFU) with a highly
pathogenic West African strain of YFV, YFV-Dakar. This route
and dose were chosen to simulate the viremia that occurs after
the initial round of YFV replication at or near the site of natural
inoculation (i.e., the skin), thus bypassing the peripheral replica-
tion sites that are resistant to YFV infection in the mouse. Ma-
caques were inoculated via subcutaneous (s.c.) injection with 550
FFU (5 × 104 TCID50) of YFV-Dakar. Upon inoculation with
YFV-Dakar, adult WT C57BL/6 mice exhibited a variable disease
course, with 6 of 10 mice exhibiting weight loss and succumbing to
disease by 14 d post inoculation (dpi) (Fig. 1A). Weight loss trends
of YFV-infected muFRGmice were comparable to those of YFV-
infected WT mice, with 10 to 20% decreases in body mass ap-
parent by 8 dpi. In contrast, hFRG mice lost weight more rapidly
following inoculation, exhibiting 10 to 25% weight loss within 4 to
5 d of infection. Three of four macaques infected with YFV
reached predetermined humane end points and required eutha-
nasia by 6 dpi, but weight loss was not a defining characteristic of
YF disease. Of note, one macaque did not display overt signs of
disease, consistent with the ∼75% lethality rate observed in this
model, as described previously (33).
To determine the viral tropism in these models, we measured
infection levels in key target tissues when the animals became
moribund or required euthanasia. For a direct comparison to
hFRG mice which became moribund within 4 to 5 d of virus
inoculation, we also evaluated tissue viral burden in muFRG
mice at this time. Greater than 1 × 106 YFV genome copies were
present in the plasma of infected macaques and hFRG mice at
these time points, whereas substantially lower levels were de-
tected in WT and muFRG mice (Fig. 1B). We observed a hep-
atotropic pattern of YFV infection in macaques and hFRG mice.
In contrast, WT and muFRG mice had high levels of infection in
the brain (Fig. 1 C and D) but not in the liver, as observed
previously (19, 35–37).
We next evaluated liver pathology in YFV-infected hosts.
Livers from YFV-infected hFRG mice exhibited a pale appear-
ance upon gross examination, with areas of apparent hemorrhage.
Histopathological analysis of livers from humans, macaques, and
hFRG mice revealed features typical of YF (15), characterized by
apoptotic and steatotic hepatocytes, areas of necrosis, and mini-
mal inflammatory tissue reaction (Figs. 1E and 2). The percentage
of liver tissue affected correlated with the plasma and liver viral
burden in YFV-infected hFRG mice (Fig. 1F). Features charac-
teristic of YFV infection in humans and macaques were isolated
to distinct patches throughout the livers of YFV-infected hFRG
mice and were completely absent in livers from YFV-infected
wild-type or muFRG mice (Fig. 2). Patches of diseased tissue in
hFRG mice localized to zones of engrafted human hepatocytes,
which could be distinguished from murine hepatocytes by their
smaller cell size, higher nuclear-to-cytoplasmic ratio, more uni-
form nuclear size, paler cytoplasm, and fumarylacetoacetate
hydrolase (FAH) staining by immunohistochemistry (38) (Figs. 2
and 3). Areas that stained positively for FAH displayed sub-
stantial overlap with areas that stained positively for YFV RNA
by in situ hybridization (Fig. 3A), and the disease features ob-
served in hematoxylin and eosin-stained tissue sections were
most prominent in areas with abundant YFV RNA (Fig. 3B).









































YFV Infection of hFRG Mice Recapitulates Key Features of Infection of
Humans and Macaques. To correlate the disease observed in YFV-
infected hFRG mice to humans, we compared key laboratory
markers associated with end-organ damage. Markers of liver
disease (e.g., alanine aminotransferase [ALT], total bilirubin,
and ammonia [NH3]) increased over the course of YFV infection
in macaques and hFRG mice, but not in muFRG mice (Fig. 4 A,
C, and D). By day 4/5, hFRG mice had reduced levels of albu-
min, indicative of a developing synthetic protein defect in the
liver (Fig. 4B). Serum creatinine, a marker of renal function, was
elevated in YFV-infected humans and macaques, but not in
YFV-infected muFRG or hFRG mice (Fig. 4E). Finally, al-
though pancreatitis was recently reported in some humans with
severe YF (39), we found no significant increase in blood lipase
in our animal models (Fig. 4F).
YFV Infection of hFRG Mice Fails to Induce Consumptive Coagulopathy.
We assessed changes in coagulation over the course of YFV
infection first by measuring prothrombin time (PT), a functional
assay that evaluates clot formation via the extrinsic pathway
(Fig. 5A). Prolongation of the PT beyond the reference range
occurred in most YFV-infected macaques and in all hFRG mice,
but not in any muFRG mice (Fig. 5B). Using factor-deficient
plasmas, we performed mixing studies to analyze the activity of
factors at various steps within the clotting cascade (Fig. 5A). We
observed decreases in coagulation factor activities in macaques
and muFRG and hFRG mice, as measured by activities of factor
VII (extrinsic pathway), factor IX (intrinsic pathway), and factors
II and X (common pathway) (Fig. 5C). However, the largest de-
creases occurred in hFRG mice. We did not detect consistent
changes in factor VIII activity (intrinsic pathway) or fibrinogen
levels (common pathway), both of which also are acute-phase
reactants.
Unlike the functional PT assay, methods for quantifying blood
D-dimer concentrations are antibody-based. Anti–D-dimer antibodies
Fig. 1. YFV is viscerotropic in hFRG mice and macaques. (A) Weight-loss curves for macaques (mac), wild-type (WT) C57BL/6J mice (gray), muFRG mice (green),
and hFRG mice (blue) following YFV inoculation. One macaque did not develop overt disease (denoted in salmon); this macaque was necropsied at day 18
post infection. (B) YFV viral load in plasma and (C) tissue homogenates, as determined by RT-qPCR. (D) Ratio of viral RNA load in brain versus liver, expressed
as a ratio of the non–log-transformed value in each individual. (E) Quantification of apoptosis/necrosis in livers from YFV-infected macaques (red), muFRG
mice (green), and hFRG mice (blue). Scoring of apoptosis/necrosis (and engraftment for hFRG mice, far right) was performed on hematoxylin- and eosin-
stained sections by two board-certified hepatopathologists blinded to YFV-infection status. Data are the average of the two scores. (F) Linear regression of
YFV burden in liver and plasma versus the percentage of liver scored as apoptosis/necrotic by examination of hematoxylin- and eosin-stained sections for YFV-
infected macaques (red) and hFRG mice (blue). Statistical significance was determined from unpaired t tests performed on log-transformed values and is
denoted by an open star (n.s.: P ≥ 0.05; ☆: P = 0.01 to 0.05; ☆☆☆☆: P < 0.0001). The number of animals (n) for each experiment is indicated in B and C.

































generally recognize species-specific epitopes, complicating com-
parison of D-dimer concentrations across species or in animals
with chimeric coagulation cascades. To examine the ability of
various D-dimer assays to detect human, macaque, and murine
D-dimers, we developed a method to generate D-dimers ex vivo
using purified human plasmin. Plasmin lyses fibrin clots, liberating
D-dimers in the process. We treated citrated plasma from unin-
fected macaques and hFRG mice with plasmin and demonstrated
our ability to detect D-dimers in each of these species (Fig. 5D).
After YFV infection, the three lethally infected macaques devel-
oped abnormally elevated blood concentrations of D-dimer within
4 to 5 d of infection (Fig. 5E). In contrast, we observed no sig-
nificant elevations in D-dimer concentration in YFV-infected
muFRG or hFRG mice (note: both human and murine D-dimer
isoforms were measured in hFRG animals (Fig. 5E). Collectively,
these data suggest that coagulopathy during YFV infection is host-
dependent. In YFV-infected humans and macaques, coagulopathy
is associated with both a synthetic defect and clotting factor con-
sumption, whereas in hFRG mice only a synthetic defect
is observed.
Discussion
The natural resistance of mice to YFV infection and disease has
hampered pathogenesis studies and the development of thera-
peutics. To some degree, this obstacle is overcome by intracranial
or i.v. inoculation of YFV, although the resulting encephalitis has
questionable relevance to the viscerotropic disease observed in
humans (40, 41). Some transgenic mice, particularly those lacking
genes involved in type I IFN signaling, have enhanced suscepti-
bility to YFV infection (17, 19, 26, 27, 28), although these animals
still fail to develop the severe liver damage and coagulopathy that
defines YF in humans (19, 28). With the possible exception of the
Syrian hamster, which develops elevated ALT and prolonged PT
but has not had D-dimer levels assessed (42, 43), NHPs remain the
only laboratory animals that recapitulate these key aspects of
human YF disease.
We developed a unique YFV infection model in FRG mice.
Comparison of FRG mice engrafted with human (hFRG) or
murine (muFRG) hepatocytes demonstrated the susceptibility of
Fig. 2. Liver pathology in YFV-infected hFRG mice is similar to YFV-infected
humans and macaques. Hematoxylin and eosin staining of FFPE liver sections
collected from moribund naive and YFV-infected humans, macaques, wild-type
mice, muFRG mice, and hFRG mice. Liver parenchyma is noticeably affected in
humans, macaques, and hFRG mice, but not in wild-type or muFRG mice. Apo-
ptotic cells, necrotic debris, and hypereosinophilic Councilman-Rocha-Lima bod-
ies (arrowheads) are seen throughout the livers of affected hosts (Scale bars, 50
μm.)
Fig. 3. YFV infects and destroys human and macaque hepatocytes, but not
murine hepatocytes. (A) Low-magnification photographs of serial FFPE liver
sections from a moribund hFRG mouse stained brown for FAH using IHC
(Left) and YFV RNA using in situ hybridization (ISH) (Right). (B) ISH for YFV
RNA in areas of prominent tissue damage in macaques and murine livers,
counterstained with hematoxylin (Scale bars, 50 μm.)









































human hepatocytes to YFV infection. This enabled the devel-
opment of a mouse model of YFV infection that recapitulates
key aspects of severe YF in humans: greater tropism of YFV in
the liver versus the brain; severe hepatitis as defined hepatocyte
necrosis; 10- to 40-fold increases in blood ALT concentrations;
and coagulopathy as defined by substantial PT prolongation.
This model also allowed us to address the relationship between
hepatitis and coagulopathy in severe YF. We first clarified the
type of coagulopathy present in patients with severe YF. This
revealed highly elevated D-dimer concentrations, which demon-
strates the presence of a consumptive coagulopathy. A consump-
tive coagulopathy also was observed in YFV-infected macaques,
but not in YFV-infected hFRG mice, despite the ability of blood
from hFRG mice to generate human D-dimers ex vivo. The
combination of a prolonged PT with no elevation in D-dimer
suggests that the coagulopathy observed in YFV-infected hFRG
mice is due principally to a decrease in clotting-factor production.
It also implies that infection and injury of human hepatocytes
alone is insufficient to cause the consumptive coagulopathy ob-
served in severe human cases of YF. Thus, in humans and NHPs,
important aspects of YF pathogenesis likely occur in cells and
tissues outside of the hepatocellular compartment.
Although consumptive coagulopathy has been hypothesized to
contribute to the hemorrhagic manifestations accompanying se-
vere YF, historically there is limited data to support this idea (15,
22). Despite all of the clinical studies of YF in humans over the
past 100 y, elevated D-dimers are described in only a few case
reports (44, 45). The lack of data regarding the development of
coagulopathy in human YF is relevant given the recent trend of
treating severe YF with plasma exchange (24). Although data on
this intervention is still emerging, preliminary results suggest that
coagulopathy may be an important factor in the development of
microthrombotic disease, multiorgan failure, and fatal outcome
of severe YF cases. As such, the human data presented herein
may provide a reference for clinicians to monitor coagulation
parameters more closely in YFV-infected patients.
Consumptive coagulopathy is caused by aberrant hyper-
activation of the coagulation cascade. Certain drugs (e.g.,
novoseven) and venom (e.g., Russell’s viper) can activate coag-
ulation factors directly, and the ability of YFV proteins to act in
a similar fashion cannot be formally excluded. However, coa-
gulopathy in the context of virus infection more often is attrib-
uted to induction of a hyperinflammatory state (i.e., “cytokine
storm”) and concomitant up-regulation of procoagulant mole-
cules, such as tissue factor (46–49). A definitive causal link be-
tween acute virus-induced inflammation and the development of
coagulopathy in viral hemorrhagic fever has been difficult to
define. Infection (and/or activation) of Kupffer and endothelial
cells is thought to play a central role in the inflammatory re-
sponse and consumptive coagulopathy that develops during
EBOV infection (23, 49–51), and in vitro studies suggest that
both of these cell types could be targets of YFV infection
(52–55). Indeed, YFV-17D–infected mice engrafted with human
immune cells exhibit higher viral loads and greater disease than
mice engrafted with murine immune cells, supporting the idea
that direct infection of immune cells also contributes to YF
Fig. 4. YFV infection is associated with laboratory abnormalities indicative of severe hepatic injury in humans, macaques, and hFRG mice, but not muFRG
mice. Clinical laboratory testing of blood from humans (black), macaques (red), muFRG mice (green), and hFRG mice (blue) was performed to assess end-organ
damage for liver [ALT (A), albumin (B), total bilirubin (C), NH3 (D)], kidney (creatinine) (E), and pancreas (lipase) (F). Human data are shown for comparison;
“day” indicates “day post inoculation” for animal models, but for humans “day” indicates “day post hospitalization.” Open circles denote preinfection values
in animal models and samples from the same individual are connected by a line. Statistical significance was determined from unpaired t tests and is denoted
by an open star (n.s.: P ≥ 0.05; ☆: P = 0.01 to 0.05; ☆☆☆: P = 0.0001 to 0.001; ☆☆☆☆: P < 0.0001). Gray areas indicate the human reference range for each
parameter, as defined by the American Board of Internal Medicine (67).

































pathogenesis (17). Thus, it is conceivable that YFV infection (or
activation) of extrahepatic cells could induce consumptive coa-
gulopathy akin to Ebola hemorrhagic fever. Additional research
is needed to determine how these extrahepatic cells modulate
YF pathogenesis and coagulopathy. Alternatively, the loss of
anticoagulant factors (e.g., tissue factor pathway inhibitor, pro-
tein C, protein S, antithrombin, and thrombomodulin) via he-
patocyte destruction, blood loss, or some other mechanism also
could result in an imbalance in the coagulation cascade that
promotes the development of consumptive coagulopathy in cases
of severe YF.
Our study has limitations, especially regarding comparisons of
YF pathogenesis among host species (i.e., human, macaque, and
mouse). First, the South American strain of YFV infecting hu-
mans in Brazil is ∼90% identical at the amino acid level to the
West African strain used in our animal models, and it is possible
Fig. 5. Coagulation factor consumption is a feature of YFV infection in humans and macaques but not in hFRG mice. (A) Simplified scheme of the coag-
ulation cascade. (B) PT in humans (black), macaques (red), muFRG mice (green), and hFRG mice (blue). (B–E) Solid symbols denote YFV-infected individuals
whereas open symbols denote uninfected ones. Dashed lines represent the limits of detection of the assay; gray areas indicate the human reference range for
each parameter, as defined by the American Board of Internal Medicine (67). (C) Coagulation factor activities determined using factor-deficient human
plasma in a PT-based assay. (D) Demonstration that plasma from macaques and hFRG mice can generate D-dimers and be detected with the assays used in this
study. (E) Plasma D-dimer concentrations in YFV-infected humans and animal models. Significance from paired t tests is denoted by an asterisk, whereas
significance from unpaired t tests is denoted by an open star (n.s.: P ≥ 0.05; ☆☆: P = 0.001 to 0.01; *P = 0.01 to 0.05; **P = 0.001 to 0.01; ***P = 0.0001
to 0.001).









































that this sequence variation could explain some of the discrep-
ancies observed between humans and animals in this study.
Second, the dose and route of infection were different for each
animal species: naturally infected humans likely were inoculated
by mosquito bite with an unknown dose in the range of 104 to 106
infectious units (56); macaques were inoculated s.c. with 5.5 ×
102 FFU (5 × 104 TCID50); and mice were inoculated i.v. with
2 × 105 FFU. However, the detection of YFV RNA in the blood
of infected humans, macaques, and mice implies that YFV cir-
culates in each of these hosts. Our study also was limited by each
host in species-specific ways. In humans, the time between YFV
inoculation and the onset of symptoms is variable (57), which
precludes a detailed analysis of the early events in pathogenesis.
The macaque model allowed for a more controlled examination
of YF over time, but the small sample size (n = 4) and lack of
overt disease in one animal results in an underpowered study for
detailed statistical analysis. The hFRG mouse model afforded a
larger sample size but fewer time points due to rapid death.
Importantly, FRG mice lack functional lymphocytes, which could
be a target of YFV infection and undoubtedly contribute to the
immune response to YFV infection in immunocompetent hu-
mans and nonhuman primates. As a result, the role of the im-
mune response in the development of coagulopathy—especially
in the context of hepatocyte infection by YFV—remains unex-
plored. Patchy engraftment of human hepatocytes also results in
a relatively disorganized liver architecture, which could modulate
YFV pathogenesis through gene expression alterations that are
unique to the hFRG model (58). The hepatocellular chimerism
in hFRG mice also creates a chimeric human–mouse coagulation
cascade. Inefficient interactions between specific human and
murine coagulation factors have been described and could im-
pact clotting depending on the percentage of chimerism in a
given individual (59, 60). For this reason, we limited our coag-
ulation analyses to functional clotting-based assays or tests that
quantify the concentration of an analyte (e.g., D-dimer) in blood
from each animal studied. While we cannot definitively exclude
the possibility that the murine coagulation system contains in-
hibitors that prevent the development of consumptive coagul-
opathy in hFRGmice, our ability to generate D-dimers in plasma
from this host ex vivo makes this less likely. Despite the limita-
tions associated with the study of YF in each host by itself, our
data provide added insight into pathogenesis and coagulopathy,
which has implications for therapeutic interventions against YF
and possibly other emerging RNA viruses (e.g., SARS-CoV-2
and Ebolavirus) that also cause coagulation defects.
Methods
Human Subjects. The human data used in this study were collected as part of an
ongoing institutional review board-approved study at the Clinical Hospital of
the University of São Paulo School of Medicine and the Infectious Diseases
Institute Emilio Ribas, São Paulo, Brazil (CAAE: 59542216.3.1001.0068). All
study participants or their legal representatives provided signed informed
consent to participate in this study. Protected health information was main-
tained in secured cabinets and electronic files using the REDCap platform on a
secured server at the School of Medicine, University of São Paulo.
Mice. All mouse experiments were conducted under a Washington University
School of Medicine Institutional Animal Care and Use Committee approved
protocol in compliance with the AnimalWelfare Act. WT C57BL/6J mice (male
and female) were purchased from The Jackson Laboratory. hFRG mice were
generated by Yecuris Corporation and maintained according to their specific
care and use guidelines. In brief, FRG triple knockout mice (Fah−/−, Rag2−/−,
and Il2rɣ−/− on a C57BL/6J background) were fed a diet supplemented orally
with nistinone (CurX Nistinone, Yecuris) in the drinking water. At 6 wk of
age, nistinone was removed from drinking water and a urokinase-type
plasminogen-activator–expressing adenoviral vector was delivered via i.v.
injection to induce hepatocellular death, which was accompanied by intra-
splenic injection of ∼5 × 105 cryopreserved human hepatocytes. Engraftment
of human hepatocytes was monitored by assessing blood concentrations of
human albumin. Only mice with human albumin levels of ≥5.0 mg/mL of
plasma (corresponding to ≥70% engraftment) were used for this study.
Engraftment of FAH+/+ murine hepatocytes into the FRG mice were gener-
ated using similar methods. Adult mice of both sexes, ages 12 to –24 wk,
were used for this study. FRG mice continued on their regular diet of PicoLab
High Energy Mouse Diet, 5LJ5 chow (LabDiet), and 3.25% wt/vol dextrose-
water during infection experiments.
Macaques. Rhesus macaques were managed in accordance with the recom-
mendations described in the Guide for the Care and Use of Laboratory
Animals of the National Institute of Health (61), the Office of Animal Wel-
fare, and the US Department of Agriculture. All animal work was approved
by the Oregon National Primate Research Center (ONPRC) Institutional An-
imal Care and Use Committee (Public Health Service Office of Laboratory
Animal Welfare Assurance #A3304-01). The ONPRC is fully accredited by the
Assessment and Accreditation of Laboratory Animal Care International. All
procedures were carried out under anesthesia induced by ketamine by
trained personnel under the supervision of veterinary staff. After infection,
trained personnel monitored animals four times each day. Animals were
euthanized humanely by veterinary staff in accordance with end-point
policies. Euthanasia was conducted under anesthesia with ketamine fol-
lowed by overdose with sodium pentobarbital. This method is consistent
with the recommendation of the American Veterinary Medical Association.
Biosafety. All aspects of this study were approved by the offices of Envi-
ronmental Health and Safety at Washington University School of Medicine
and ONPRC prior to the initiation of this study. All personnel working in
rooms in which pathogenic YFV was used were vaccinated at least 2 wk prior
to initiating work. Studies involving animals were performed in an A-BSL-3
suite by personnel equipped with powered air purifying respirators. Non-
animal studies involving infectious virus were performed in a BSL-3 labora-
tory with appropriate barrier personal protective equipment.
Viruses. The YFV-DakH1279 strain (YFV-Dakar) was isolated from a human in
Senegal in 1965 and obtained from the World Reference Center for
Emerging Viruses and Arboviruses (K. Plante, R, Tesh, and S. Weaver, Uni-
versity of Texas Medical Branch). The viral stock used to infect mice was
grown on Vero-WHO cells that were maintained in Dulbecco’s Modified
Eagle Media with 5% fetal bovine serum. Supernatant was harvested upon
observation of cytopathic effect. Debris was removed by centrifugation, and
stocks were aliquoted and stored at −80 °C. The stock used to infect rhesus
macaques was passaged through a single macaque and then propagated in
C6/36 cells. Mice were inoculated with 2 × 105 FFU of YFV via inoculation of
50 μL into the retroorbital venous plexus. Macaques were inoculated via a
s.c. route (1.0 mL divided among five injection sites) with a total of 5.5 × 102
FFU (i.e., 5 × 104 TCID50) (62).
Focus-Forming Assay. Vero-WHO cells were seeded at a density of 2.5 × 104
cells per well in flat-bottom 96-well tissue culture plates. The following day,
medium was removed and replaced with 100 μL of 10-fold serial dilutions of
virus containing solutions. Two hours later, 135 μL of methylcellulose overlay
was added. Plates were incubated for 48 h and then fixed with 4% para-
formaldehyde in phosphate-buffered saline for 10 min, followed by per-
meabilization with saponin-containing buffer. Plates were incubated
overnight at 4 °C in 100 μL of permeabilization buffer containing a mixture
of 4G2 and E60 (63–65) monoclonal antibodies, each at 0.5 μg/mL. Goat anti-
mouse secondary antibody (Sigma) was used at a concentration of 1:2,000,
and foci were scanned and quantitated on a Biospot plate reader (Cellular
Technology).
Quantitative RT-PCR. We developed a primer/probe set for real-time PCR of
YFV based upon the assay developed in ref. 66 that targets the 5′ untranslated
region: F—5′-AGGTGCATTGGTCTGCAAAT-3′; R—5′-TCTCTGCTAATCGCTCAAIG-
3′; P—5′-/56-FAM/GTTGCTAGGCAATAAACACATTTGGA/3BHQ_1/-3′. An RNA stan-
dard was made by amplifying a 590-bp product containing the real-time PCR
primer-binding sites from the YFV-Dakar genome (F—5′-AGGTGCATTGGT
CTGCAAAT-3′; R—5′-AATCTGGGCACCAGAACTTG-3′) and cloning this into
Zero Blunt PCR vector (Invitrogen). After linearization of the construct
(HindIII, New England BioLabs), transcription was performed in vitro for 6 h
(MEGAscript T7 transcription kit, Invitrogen) followed by purification
(MEGAclear transcription cleanup kit, Invitrogen), quantification, and dilu-
tion to a concentration of 1 × 1010 transcript copies/microliter. Ten-fold di-
lutions of this transcript were used as a standard curve, which was linear
over eight orders of magnitude and sensitive down to 10 copies of RNA
transcript per reaction.

































Viral RNA was extracted on the KingFisher Flex System (ThermoFisher)
according to the manufacturer’s instructions using the MagMAX Viral RNA
or mirVana Total RNA kits for plasma and tissues, respectively. RNA was
reverse-transcribed and amplified using the TaqMan RNA-to-CT 1-Step Kit
(ThermoFisher) on the QuantStudio 6 Flex Real-Time PCR System. Reverse
transcription was carried out at 48 °C for 15 min followed by 2 min at 95 °C.
Amplification was accomplished over 50 cycles as follows: 95 °C for 15 s and
60 °C for 1 min. The reaction mixture contained final concentrations of
primers and probes of 500 and 100 nM, respectively.
Tissue Collection. Mice were sedated with i.p. administration of ketamine.
Blood was drawn from the right ventricle. The entire cardiovascular tree was
perfused with ∼20 mL of saline administered via canulation of the left
ventricle. Midway through perfusion, the superior vena cava was transected
to allow for outflow of fluid from the vasculature. The left liver lobe was
added to 10 mL of 10% neutral buffered formalin. The remaining lobes
were snap-frozen in tubes. The brain was transected in the sagittal plane:
one hemisphere was placed in 10% neutral buffered formalin and the other
half was snap-frozen. A similar euthanasia and perfusion scheme was per-
formed on macaques.
Coagulation Factor Assays. For mice, PT was measured from whole blood,
obtained either by phlebotomy of a facial vein (for survival procedures) or
cardiac puncture (for terminal procedures) using the point-of-care Coa-
guChek instrument (Roche). For macaques, PT was performed on the Coat-
ron X Pro (Teco) using citrated plasma according to the manufacturer’s
instructions. For both mice and macaques, levels of factors II, VII, VIII, IX, and
X were measured on the Coatron X pro using a PT-based assay according to
the manufacturer’s recommendations. All coagulation assays were per-
formed in a biosafety cabinet under BSL-3 conditions.
D-Dimer Measurement. Plasma D-dimer concentrations were analyzed in YF
patients by the clinical laboratory at the University of Sao Paulo using
HemosIL D-dimer HS 500, an automated, latex-enhanced turbidimetric im-
munoassay for the quantitative determination of D-dimer, according to the
manufacturer’s instructions. The upper limit of the analytical measurement
range for this assay is 10,000 ng/mL. Some of the clinical samples that reg-
istered at this level were diluted and retested. For consistency, all
values >10,000 ng/mL have been reported as 10,000 ng/mL. Human D-dimer
testing on citrated plasma from hFRG mice was performed on the Coatron X
pro using the Blue D-dimer latex agglutination assay (Teco) according to the
manufacturer’s instructions. D-dimer testing on citrated plasma from ma-
caques was performed on the Coatron X pro using Stago’s D-Di Liatest
(Stago Diagnostica); control samples were used to calibrate the Stago assay
for use on the Coatron X pro. Murine D-dimer concentrations were assayed
using the Mouse D2D(D-Dimer) ELISA Kit (Elabscience). The in vitro D-dimer
generation assay was performed as follows: 10 μL of human plasmin
(Millipore-Sigma), reconstituted to 1 unit/mL in Hank’s Balanced Salt Solu-
tion (HBSS), was added to 30 μL of citrated plasma, vortexed, and incubated
at 37 °C for 10 min. A total of 10 μL of PT reagent was added, vortexed, and
incubated at 37 °C for 20 min. Then 25 μL of this mixture was tested for the
formation of D-dimer using the Coatron X pro latex agglutination D-dimer
assay. This assay was used to determine the validity of each assay for each
species. No latex-agglutination assay for mouse D-dimer was identified, and
so D-dimer analysis was not performed on muFRG or WT mice.
Clinical Chemistries. Prior to analysis, citrated plasma was mixed 1:9 with 10%
Triton X-100 in HBSS (1% final volume of Triton-X-100) and then incubated
at room temperature for 1 h to inactivate infectious virus. This method of
virus inactivation was found to not affect the clinical chemistry analyses.
Specimens were analyzed using the Catalyst One Chemistry Analyzer (IDEXX
Laboratories). Some specimens required dilutions to achieve an ALT value
within the analytical measurement range; in these instances, dilution was
performed in HBSS (or deionized H2O for macaque samples), and the value
was corrected by the final dilution factor. Human-specific albumin was
measured using the Human Albumin ELISA Kit (Bethyl Laboratories).
Histological Assessment. Hematoxylin- and eosin-stained formalin-fixed
paraffin-embedded (FFPE) histologic sections of mouse and nonhuman pri-
mate livers were reviewed by two board-certified fellowship-trained hep-
atopathologists (L.I.K. and K.B.) for percentage of engraftment (hFRG group
only) and percentage of necrosis (all groups) in consultation with a Brazilian
pathologist (A.N.D.-N.) experienced in examining YFV-infected livers. The
pathologists were blinded to YFV infection status within individual groups.
Whole slide images were obtained using an Aperio CS scanner (Leica) and
viewed using the image analysis software HALO (Indica Labs, v2.2.1870.8).
Individual microscopic images were taken using an Olympus BX51/3 or Nikon
Eclipse E3400 microscope with attached camera at the magnifications as
indicated in each figure legend.
In Situ Hybridization and Immunohistochemistry. Viral RNA was visualized by
in situ hybridization using a custom YFV-Dakar probe and the RNAscope 2.0
HD detection kit (Advanced Cell Diagnostics) according to the manufac-
turer’s instructions. Immunohistochemical (IHC) staining of FFPE sections for
FAH was performed using a polyclonal rabbit antibody (Invitrogen catalog
#PA5-42050) after standard deparaffinization, rehydration, peroxidase
blocking, and antigen retrieval with boiling citrate solution (pH of 6) for
30 min.
Statistical Analysis. Statistical analyses were performed in Prism 7 (Graphpad
Software). Each statistical test used is denoted in the figure legends.
Data Availability. All study data are included in the article and supporting
information.
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